In vitro cytotoxicity of polyphosphoester as a novel injectable alveolar replacement material.

Department of Orthodontics, Tongji Hospital, Wuhan 430022, China.
Journal of Huazhong University of Science and Technology (Impact Factor: 0.58). 10/2008; 28(5):604-7. DOI: 10.1007/s11596-008-0526-6
Source: PubMed

ABSTRACT The aim of this study was to investigate the in vitro cytotoxicity of polyphosphoester polymer used as a novel injectable alveolar bone substitutes for controlled delivery of tetracycline. Cell culture medium was exposed to the polymer (0.01-10 mg/mL) for 24 h. The L-929 mouse fibroblasts were then exposed to the treated cell culture medium for 24 h. Finally, cell viability and growth were assessed by using MTT assay and Alamar Blue assay. No significant cytotoxicity of the polyphosphoester against L-929 mouse fibroblasts was observed at a concentration up to 10 mg/mL (P>0.05). The two evaluation methods showed no significant differences (P>0.05). This study suggests that polyphosphoester does not demonstrate any significant toxic effects to cells in vitro and has the potential to be used both as a medical device and as scaffolds in tissue engineering applications.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Poly(D,L-lactide-co-glycolide) (PLGA, 75/25) microspheres loaded with bovine serum albumin (BSA) were prepared using the W/O/W emulsification solvent evaporation technique. The cytotoxicity in vitro of PLGA microspheres was investigated and the BSA release from PLGA microspheres was also studied. Scanning electron micrographs showed that the PLGA microspheres were regular and the surface was smooth. BSA release typically began with an initial burst and then became steady. Analysis of the PLGA microspheres cytotoxicity showed that they had no cytotoxic effect and behaved very similar to the negative control of polystyrene. The hemolysis rate of the PLGA microspheres was 0.148%, suggesting it had no potential to induce hemolysis. The results show that PLGA microspheres may provide a useful controlled release protein drug system for used in pharmaceutics.
    Journal of Macromolecular Science®. 06/2011; Part B: Physics(Vol. 50):1154-1161.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Utilization of polymers as biomaterials has greatly impacted the advancement of modern medicine. Specifically, polymeric biomaterials that are biodegradable provide the significant advantage of being able to be broken down and removed after they have served their function. Applications are wide ranging with degradable polymers being used clinically as surgical sutures and implants. In order to fit functional demand, materials with desired physical, chemical, biological, biomechanical and degradation properties must be selected. Fortunately, a wide range of natural and synthetic degradable polymers has been investigated for biomedical applications with novel materials constantly being developed to meet new challenges. This review summarizes the most recent advances in the field over the past 4 years, specifically highlighting new and interesting discoveries in tissue engineering and drug delivery applications.
    Journal of Polymer Science Part B Polymer Physics 06/2011; 49(12):832-864. · 2.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cathelicidin-BF-30 (BF-30), a water-soluble peptide isolated from the snake venom of Bungarus fasciatus containing 30 amino acid residues, was incorporated in poly(D,L-lactide-co-glycolide) (PLGA) 75∶25 microspheres (MS) prepared by a water in oil in water W/O/W emulsification solvent extraction method. The aim of this work was to investigate the stability of BF-30 after encapsulation. D-trehalose was used as an excipient to stabilize the peptide. The MS obtained were mostly under 2 µm in size and the encapsulation efficiency was 88.50±1.29%. The secondary structure of the peptide released in vitro was determined to be nearly the same as the native peptide using Circular Dichroism (CD). The ability of BF-30 to inhibit the growth of Escherichia coli was also maintained. The cellular relative growth and hemolysis rates were 92.16±3.55% and 3.52±0.45% respectively.
    PLoS ONE 01/2014; 9(6):e100809. · 3.53 Impact Factor